Skip to main content

Drug Interactions between eculizumab and Gamimune N 10%

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

immune globulin intravenous eculizumab

Applies to: Gamimune N 10% (immune globulin intravenous) and eculizumab

Consumer information for this interaction is not currently available.

ADJUST DOSE: According to the prescribing information for eculizumab, intravenous immunoglobulin (IVIg) treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as eculizumab, which may lead to decreased serum concentrations and reduced effectiveness of eculizumab. The clinical significance is unknown. Drug interaction studies have not been conducted with eculizumab in patients treated with IVIg.

MANAGEMENT: Due to the potential for reduced eculizumab effectiveness, close clinical monitoring is recommended if coadministration with IVIg is clinically necessary. According to some authorities, administering a supplemental dose of eculizumab in patients receiving concomitant IVIg is advised. The supplemental dose of eculizumab is dependent on the most recent dose of eculizumab. For patients receiving eculizumab doses less than or equal to 600 mg, a supplemental eculizumab dose of 300 mg per IVIg cycle should be administered. For patients receiving eculizumab doses greater than or equal to 900 mg, a supplemental eculizumab dose of 600 mg per IVIg cycle should be administered. The supplemental eculizumab dose should be administered as soon as possible after the IVIg cycle. Additional consultation with individual package labeling, as well as relevant institutional protocols, may be advisable for further guidance.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.